Aprepitant

Drug Profile

Aprepitant

Alternative Names: Emend; L-754030; MK-0869; MK-869; ONO-7436

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Fudan University Shanghai Cancer Center; Hunan Province Tumor Hospital; Merck & Co; Ono Pharmaceutical
  • Class Antidepressants; Antiemetics; Fluorobenzenes; Morpholines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 01 Sep 2016 Merck completes a phase II trial in Postoperative nausea and vomiting (Prevention, In adolescents, In children, In infants, In neonates) in USA, Hungary, Spain, Italy and Czech Republic (NCT01732458/EudraCT2011-006006-27)
  • 17 Apr 2016 Biomarkers information updated
  • 22 Oct 2015 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of aprepitant (80mg nd 125mg hard capsules) for the prevention of chemotherapy-induced nausea and vomiting in adults and adolescents from the age of 12
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top